We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

195 hedge funds and large institutions have $2.79B invested in Medicines Co in 2016 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 79 increasing their positions, 63 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 63

0% less call options, than puts

Call options by funds: $55M | Put options by funds: $55.1M

3% less funds holding

Funds holding: 201195 (-6)

11% less funds holding in top 10

Funds holding in top 10: 98 (-1)

12% less capital invested

Capital invested by funds: $3.16B → $2.79B (-$367M)

13% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 31

Holders
195
Holders Change
-6
Holders Change %
-2.99%
% of All Funds
4.88%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.2%
New
27
Increased
79
Reduced
63
Closed
31
Calls
$55M
Puts
$55.1M
Net Calls
-$107K
Net Calls Change
-$67.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$360M +$5.94M +167,567 +2%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$336M +$1.14M +32,256 +0.3%
BFA
3
BlackRock Fund Advisors
California
$232M +$27.5M +775,226 +13%
Vanguard Group
4
Vanguard Group
Pennsylvania
$196M +$7.19M +202,831 +4%
CM
5
Corvex Management
New York
$110M +$5.16M +145,457 +5%
PHS
6
PFM Health Sciences
California
$92.2M +$34.4M +969,243 +55%
State Street
7
State Street
Massachusetts
$69.8M -$313K -8,818 -0.4%
BIT
8
BlackRock Institutional Trust
California
$61.7M +$4.11M +115,940 +7%
SCM
9
Sarissa Capital Management
Connecticut
$59.5M
BM
10
Bridger Management
New York
$55.1M -$16.8M -473,486 -23%
UBS AM
11
UBS AM
Illinois
$52.6M -$9.07M -255,665 -14%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$49.9M -$1.07M -30,267 -2%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$49.2M -$483K -13,630 -0.9%
Franklin Resources
14
Franklin Resources
California
$48.3M -$532K -15,000 -1%
Invesco
15
Invesco
Georgia
$48.2M -$2.14M -60,295 -4%
PA
16
Pinnacle Associates
New York
$46.8M +$15.1M +426,978 +45%
AllianceBernstein
17
AllianceBernstein
Tennessee
$43.1M +$6.3M +177,650 +16%
First Eagle Investment Management
18
First Eagle Investment Management
New York
$35.8M +$1.22M +34,400 +3%
JP Morgan Chase
19
JP Morgan Chase
New York
$32.8M +$11.2M +314,917 +48%
IAM
20
Iridian Asset Management
Connecticut
$32.2M +$33.6M +948,420 New
Wells Fargo
21
Wells Fargo
California
$29.9M -$79K -2,227 -0.3%
Northern Trust
22
Northern Trust
Illinois
$28.9M +$291K +8,209 +1%
BC
23
Boxer Capital
California
$28.1M +$4.55M +128,198 +18%
Bank of America
24
Bank of America
North Carolina
$28.1M +$15.4M +434,997 +111%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$27.7M -$1.21M -34,081 -4%

MDCO Hedge Fund Activity: Q4 2016 in Review

195 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q4 2016, worth a combined $2.79B — down 12% from $3.16B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of MDCO and 27 opened new positions — a net loss of 4 holders — while 63 trimmed existing stakes and 79 added.

The largest buyer was PFM Health Sciences, adding an estimated $34.4M. The largest seller was Camber Capital Management, exiting entirely with an estimated $75.5M sold.

  • 195 institutional investors held Medicines Co (MDCO) as of Q4 2016, down from 201 in Q3 2016.
  • Funds reported $2.79B of Medicines Co stock for Q4 2016, down 12% quarter-over-quarter.
  • 27 funds opened new Medicines Co positions in Q4 2016 and 31 closed out, a net change of -4 holders.
  • The largest Medicines Co buyer in Q4 2016 was PFM Health Sciences, an estimated $34.4M added.
  • The largest Medicines Co seller in Q4 2016 was Camber Capital Management, an estimated $75.5M sold.

Based on aggregated 13F filings for Q4 2016.